Analysis of information sources in references of the Wikipedia article "A1C" in English language version.
Conclusions: A strategy of intensive glucose control, involving gliclazide (modified release) and other drugs as required, that lowered the glycated hemoglobin value to 6.5% yielded a 10% relative reduction in the combined outcome of major macrovascular and microvascular events, primarily as a consequence of a 21% relative reduction in nephropathy(Clinical trial number NCT00145925 for "Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes" at ClinicalTrials.gov)
Hospitals should ensure that the correct term for HbA1c — glycated haemoglobin — is now to be found in laboratory manuals.
Conclusions: A strategy of intensive glucose control, involving gliclazide (modified release) and other drugs as required, that lowered the glycated hemoglobin value to 6.5% yielded a 10% relative reduction in the combined outcome of major macrovascular and microvascular events, primarily as a consequence of a 21% relative reduction in nephropathy(Clinical trial number NCT00145925 for "Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes" at ClinicalTrials.gov)
Conclusions: A strategy of intensive glucose control, involving gliclazide (modified release) and other drugs as required, that lowered the glycated hemoglobin value to 6.5% yielded a 10% relative reduction in the combined outcome of major macrovascular and microvascular events, primarily as a consequence of a 21% relative reduction in nephropathy(Clinical trial number NCT00145925 for "Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes" at ClinicalTrials.gov)
Hospitals should ensure that the correct term for HbA1c — glycated haemoglobin — is now to be found in laboratory manuals.
Conclusions: A strategy of intensive glucose control, involving gliclazide (modified release) and other drugs as required, that lowered the glycated hemoglobin value to 6.5% yielded a 10% relative reduction in the combined outcome of major macrovascular and microvascular events, primarily as a consequence of a 21% relative reduction in nephropathy(Clinical trial number NCT00145925 for "Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes" at ClinicalTrials.gov)
Hospitals should ensure that the correct term for HbA1c — glycated haemoglobin — is now to be found in laboratory manuals.
Hospitals should ensure that the correct term for HbA1c — glycated haemoglobin — is now to be found in laboratory manuals.
